• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Nonprofit takes risk out of device development for Medtronic

Nonprofit takes risk out of device development for Medtronic

November 15, 2010 By MedCity News

MedCity News logo

For companies like Medtronic Inc. (NYSE:MDT), developing breakthrough technologies to treat untreatable diseases can be expensive and have little promise of financial returns.

The risk is high enough for — even companies as well-resourced as Fridley, Minn.-based Medtronic — that alternative funding sources are welcomed and highly sought after.

Last week, CHDI Foundation, a not-for-profit research organization, said it would “initially” pay up to 50 percent of clinical costs of a drug-device therapy being developed by Medtronic and Alnylam Pharmaceutical Inc. (NSDQ:ALNY) to treat Huntington’s disease. That translates into millions of dollars of free research support for the two companies.

“That’s a substantial amount of money from a not-for-profit,” Lothar Krinke, Medtronic’s vice president of research and business development for the company’s neuromodulation unit, told MedCity News. “But what’s most important to me is to have a third party endorsement … that we are moving in the right direction,” he said.

The unique, three-way partnership may foretell a future business model in which medical device makers and drug companies collaborate with outside organizations to cut costs and speed therapies to market.

It now takes an average of 15 years, and sometimes billions of dollars, to commercialize a drug in the United States, according to Tufts University‘s Center for the Study of Drug Development. With dozens of drug patents set to expire over the next few years, pharma companies are racing to replace the revenue that will be lost.

“Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the research-based drug industry brings new products to market,” CSDD said.

Advances in DNA research, including the creation of RNAi proteins that “turn on” and “shut off” certain genes that cause diseases like Huntington’s, have so far failed to translate into more medicines.

Between 1950 and 2008, the Food & Drug Administration approved 1,222 therapies, but the number of drug approvals have remained constant since 1990.

“The reason’s simple: Biotech hasn’t reduced the inherent risk in drug discovery and development,” according a recent report by PricewaterhouseCoopers.”Biotech companies don’t develop new medicines much more quickly or economically than pharma companies do.”

The average development times for technologies like RNAi actually are slightly longer than they are for regular drugs — 97.7 months versus 90.3 months — according to the report. Average development costs also are much the same — $1.24 billion vs. $1.32 billion. And the overall success rate for biotech drugs still is only 9.1 percent, compared with 6.7 percent for regular pharmaceuticals.

That’s why partnering with medical device firms could pay dividends for pharma. For one thing, experts say companies like Medtronic excel at efficiently managing clinical trials. But more importantly, Medtronic designs devices that can effectively deliver drugs to the body.

“In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially,” according to the Greystone Research consulting firm. “The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution. It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems.”

For example, Medtronic is working on an implantable infusion system that can deliver Alnylam’s RNAi therapy to the central nervous system. The companies hope the drug will spread well beyond the infusion site and reach areas of the brain affected by Huntington’s, a progressive, degenerative disease that causes brain cells to waste away. About 120,000 people suffer from the disease in the United States.

Under the 50-50 partnership, Medtronic will commercialize the therapy in the United States and Europe. In exchange for funding clinical development of the drug/device product to its launch, Alnylam will receive a proportional share of the profits in the United States, and royalties and milestone payments in Europe.

“These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories,” Greystone said. “The growth of protein drug products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to targets.”

But what makes the Medtronic/Alnylam partnership so interesting is the role of CHDI Foundation, a private not-for-profit organization that focuses on Huntington’s. Though the group solicits research proposals, it was CHDI that offered to help fund the Medtronic/Alnylam project, Krinke of Medtronic said.

That a not-for-profit group would subsidize the work of two for-profit corporations that have plenty of money might have been unthinkable, not so long ago. Medtronic alone spends about $1 billion a year on research and development.

“However, I’ve observed that the non-profit world folks are getting more aggressive in active funding,” Krinke said.”They are starting to change their minds — about funding corporate research. They want us to move faster and get new therapies that they care about. ‘We don’t care about where it comes from. We will put in the money to help.'”

The Michael J. Fox Foundation for Parkinson’s Research, which was founded by the veteran film and television actor last year spent $10.2 million on industry projects, according to its annual report. The foundation is working with 55 industry groups, including biotechnology and pharmaceutical companies.

“The greater goal of the Foundation’s ‘de-risking’ strategy is to create momentum and induce industry players to commit their own significant resources to pre-clinical and clinical Parkinson’s therapeutic development programs,” according to the annual report.

“We look for leverage everywhere,” said MJFF co-founder Debi Brooks. “That means identifying the projects where it’s a good bet that our investment of, say, a few hundred thousand dollars can create a tipping point and increase the odds of a company investing millions down the line.”

Medtronic officials say they welcome future support. “The door is open,” spokesman Brian Henry said.

Filed Under: Business/Financial News, Drug-Device Combinations, News Well, Research & Development

In case you missed it

  • Abbott imaging catheter recall flagged as Class I by FDA
  • Will Johnson & Johnson buy Boston Scientific?
  • Needham & Co. downgrades Medtronic, Zimmer Biomet shares
  • DoMore Diagnostics wins CE mark for AI algorithm that predicts colorectal cancer outcomes
  • Quidel, Ortho Clinical Diagnostics combine to form in vitro diagnostics company
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
  • U of Maryland scientist to set up NIH’s new Advanced Research Projects Agency for Health
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
  • FDA grants IDE for MedAlliance’s sirolimus-eluting balloon
  • Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
  • Bigfoot Biomedical adds former Insulet VP as chief commercial officer
  • Medtronic, DaVita to form new kidney care company
  • Medtronic stock down on Q4 earnings miss
  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid

RSS From Medical Design & Outsourcing

  • Download COMSOL News Special Edition Biomedical
    Get instant access to this special edition of COMSOL News where you will read user stories that showcases how simulation enables engineers, researchers, and scientists explore and analyze biomedical designs. Download Now.       The post Download COMSOL News Special Edition Biomedical appeared first on Medical Design and Outsourcing.
  • Qosina adds new tube-to-tube barb connectors
    Qosina has added 25 new tube-to-tube barb connectors to its portfolio, the OEM single-use component supplier for the medical and pharmaceutical industries said this week. Ronkonkoma, New York-based Qosina said its inventory of tube-to-tube barb connectors is available in more than 500 configurations. The connectors can fit inner tube diameters between 1/32 in and 1… […]
  • Abbott imaging catheter recall flagged as Class I by FDA
    The FDA has identified the Abbott (NYSE:ABT) recall of its Dragonfly OpStar Imaging Catheter as a Class I recall. That’s the most serious level of a medical device recall, carrying the risk of serious injury or death. Five incidents, one injury and zero deaths were reported when Abbott initiated the recall on April 11. The… […]
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
    Zimmer Biomet (NYSE:ZBH) today announced additional responsibilities for Investor Relations SVP and Chief Communications Officer Keri Mattox. Mattox’s new title at the Warsaw, Indiana-based orthopedics company is chief communications and administration officer. She will be responsible for “building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement… […]
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
    Medtronic CEO Geoff Martha today said a “catastrophic explosion” in Medtronic’s supply chain for packaging and a shortage of resins were the biggest issues hurting the company’s fourth-quarter performance. Fridley, Minnesota-based Medtronic (NYSE:MDT) reported about $350 million less in sales than analysts were expecting for the quarter, which ended April 29. Martha said about 75%… […]
  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maplewood, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions,… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS